Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia

References

• ADA, APAConsensus development conference on antipsychotic drugs and obesity and diabetesDiabetes Care20042759660114747245
   PubMed Web of Science ®Google Scholar
• AmanMGDe SmedtGDerivanADouble-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligenceAm J Psychiatry200215913374612153826
   PubMed Web of Science ®Google Scholar
• ArmenterosJLWhitakerAHWeliksonMRisperidone in adolescents with schizophrenia: an open pilot studyJ Am Acad Child Adolesc Psychiatry1997366947009136505
   PubMed Web of Science ®Google Scholar
• BiedermanJMickEHammernessPOpen-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age childrenBiol Psychiatry2005a585899416239162
   PubMed Web of Science ®Google Scholar
• BiedermanJMickEWozniakJAn open-label trial of risperidone in children and adolescents with bipolar disorderJ Child Adolesc Psychopharmacol2005b15311715910215
   PubMed Web of Science ®Google Scholar
• CorrellCUWeight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trialsJ Am Acad Child Adolesc Psychiatry20074668770017513981
   PubMed Web of Science ®Google Scholar
• DicksonRAGlazerWMNeuroleptic-induced hyperprolactinemiaSchizophr Res199935SupplS758610190228
   PubMed Web of Science ®Google Scholar
• DunbarFKusumakarVDanemanDGrowth and sexual maturation during long-term treatment with risperidoneAm J Psychiatry20041619182015121661
   PubMed Web of Science ®Google Scholar
• FindlingRLKusumakarVDanemanDProlactin levels during long-term risperidone treatment in children and adolescentsJ Clin Psychiatry2003641362914658952
   PubMed Web of Science ®Google Scholar
• FindlingRLMcNamaraNKBranickyLAA double-blind pilot study of risperidone in the treatment of conduct disorderJ Am Acad Child Adolesc Psychiatry2000395091610761354
   PubMed Web of Science ®Google Scholar
• FrazierJAMeyerMCBiedermanJRisperidone treatment for juvenile bipolar disorder: a retrospective chart reviewJ Am Acad Child Adolesc Psychiatry199938960510434487
   PubMed Web of Science ®Google Scholar
• GaffneyGRPerryPJLundBCRisperidone versus clonidine in the treatment of children and adolescents with Tourette’s syndromeJ Am Acad Child Adolesc Psychiatry200241330611886028
   PubMed Web of Science ®Google Scholar
• GardnerDMBaldessariniRJWaraichPModern antipsychotic drugs: a critical overviewCMAJ200517217031115967975
   PubMed Web of Science ®Google Scholar
• GothelfDApterAReidmanJOlanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophreniaJ Neural Transm20031105456012721815
   PubMed Web of Science ®Google Scholar
• HaasMUnisASCopehhaverMEfficacy and Safety of Risperidone in Adolescents with SchizophreniaAmerican Psychiatric Association Annual Meeting2007221
   Google Scholar
• HowesOSmithSHyperprolactinaemia caused by antipsychotic drugs. Endocrine antipsychotic side effects must be systemically assessedBMJ2002324127812028991
   PubMed Web of Science ®Google Scholar
• KinonBJGilmoreJALiuHHyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trialsPsychoneuroendocrinology200328Suppl 2698212650682
   PubMed Web of Science ®Google Scholar
• KowatchRADelBelloMPPharmacotherapy of children and adolescents with bipolar disorderPsychiatr Clin North Am2005283859715826738
   PubMed Web of Science ®Google Scholar
• LambETop 200 Prescription Drugs of 2006Pharmacy Times2007
   Google Scholar
• MaloneRPMaislinGChoudhuryMSRisperidone treatment in children and adolescents with autism: short- and long-term safety and effectivenessJ Am Acad Child Adolesc Psychiatry200241140711837403
   PubMed Web of Science ®Google Scholar
• MarsdenCDJennerPThe pathophysiology of extrapyramidal side-effects of neuroleptic drugsPsychol Med19801055726104342
   PubMed Web of Science ®Google Scholar
• MasiGCosenzaAMucciMA 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidoneJ Clin Psychiatry20036410394714628979
   PubMed Web of Science ®Google Scholar
• Matsui-SakataAOhtaniHSawadaYReceptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitusDrug Metab Pharmacokinet2005203687816272755
   PubMedGoogle Scholar
• McCrackenJTMcGoughJShahBRisperidone in children with autism and serious behavioral problemsN Engl J Med20023473142112151468
   PubMed Web of Science ®Google Scholar
• McDougleCJHolmesJPBronsonMRRisperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label studyJ Am Acad Child Adolesc Psychiatry199736685939136504
   PubMed Web of Science ®Google Scholar
• MillerALHallCSBuchananRWThe Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 updateJ Clin Psychiatry200465500815119912
   PubMed Web of Science ®Google Scholar
• MozesTEbertTMichalSEAn open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophreniaJ Child Adolesc Psychopharmacol20061639340316958565
   PubMed Web of Science ®Google Scholar
• OgdenCLYanovskiSZCarrollMDThe epidemiology of obesityGastroenterology2007132208710217498505
   PubMed Web of Science ®Google Scholar
• PatelNCCrismonMLHoagwoodKTrends in the use of typical and atypical antipsychotics in children and adolescentsJ Am Acad Child Adolesc Psychiatry2005445485615908837
   PubMed Web of Science ®Google Scholar
• PavuluriMNHenryDBCarbrayJAOpen-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric maniaJ Affect Disord2004a82Suppl 1S1031115571784
   PubMed Web of Science ®Google Scholar
• PavuluriMNHenryDBDevineniBA pharmacotherapy algorithm for stabilization and maintenance of pediatric bipolar disorderJ Am Acad Child Adolesc Psychiatry2004b438596715213587
   PubMed Web of Science ®Google Scholar
• PettyRGProlactin and antipsychotic medications: mechanism of actionSchizophr Res199935Supp lS677310190227
   PubMed Web of Science ®Google Scholar
• RatzoniGGothelfDBrand-GothelfAWeight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective studyJ Am Acad Child Adolesc Psychiatry2002413374311886029
   PubMed Web of Science ®Google Scholar
• SaitoECorrellCUGallelliKA prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agentsJ Child Adolesc Psychopharmacol200414350815650492
   PubMed Web of Science ®Google Scholar
• SaxenaKChangKSteinerHTreatment of aggression with risperidone in children and adolescents with bipolar disorder: a case seriesBipolar Disord200684051016879141
   PubMed Web of Science ®Google Scholar
• SikichLHamerRMBashfordRAA pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trialNeuropsychopharmacology2004291334514583740
   PubMed Web of Science ®Google Scholar
• SnyderRTurgayAAmanMEffects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQsJ Am Acad Child Adolesc Psychiatry20024110263612218423
   PubMed Web of Science ®Google Scholar
• van BruggenJTijssenJDingemansPSymptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophreniaInt Clin Psychopharmacol200318341614571154
   PubMed Web of Science ®Google Scholar
• ZalsmanGCarmonEMartinAEffectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label studyJ Child Adolesc Psychopharmacol2003133192714642020
   PubMed Web of Science ®Google Scholar